Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary antifungal prophylaxis with caspofungin or fluconazole plus posaconazole in HSCT for thalassemia major
ChiCTR2200056192Phase 4Recruiting
- Sponsor
- Guangzhou Women and Children's Medical Center
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4 trial of posaconazole, caspofungin and fluconazole in invasive mycoses (2 arms), sponsored by Guangzhou Women and Children's Medical Center. Primary endpoint: Incidence of invasive fungal disease (proven and probable). Started Jan 2021; status: recruiting.
02
Drugs
posaconazolecaspofunginfluconazole
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on ChiCTR2200056192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056192.